Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.45 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4964376 | 0.77 | RAB9A (0.60) | RAB9APOLBKMT2AMEN1NPC1 | |
| SCHEMBL4964622 | 0.77 | RAB9A (0.60) | RAB9APOLBKMT2AMEN1NPC1 | |
| SCHEMBL4962236 | 0.76 | FAAH (0.54) | RAB9APOLBKMT2AMEN1P2RY14 | |
| SCHEMBL5517970 | 0.76 | FAAH (0.54) | RAB9APOLBKMT2AMEN1P2RY14 | |
| SCHEMBL4965304 | 0.74 | EPHX1 (0.70) | POLBKMT2AMEN1BAZ1APRMT3 | |
| SCHEMBL8601330 | 0.74 | NPC1 (0.50) | RAB9APOLBKMT2AMEN1NOTUM | |
| SCHEMBL11599130 | 0.74 | ATM (1.00) | ATMRAB9APOLBKMT2AABCC1 | |
| SCHEMBL3310740 | 0.74 | MEN1 (0.63) | RAB9APOLBKMT2AMEN1P2RY14 | |
| SCHEMBL27389314 | 0.74 | MEN1 (0.76) | RAB9APOLBKMT2AMEN1P2RY14 | |
| SCHEMBL4963936 | 0.74 | MGLL (0.53) | POLBKMT2AMEN1P2RY14NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101351495-A | fatty acid amide hydrolase inhibitors | ORGANON NV (NL) | 2009-01-21 | — | — | CN | disclosed |
| EP-1969051-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. Organon (NL) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008024139-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007079180-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ABHD6 | ATM 4780/4885RAB9A 2202/4885POLB 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.